REVIEW
Cancer Advances 2025;8:e25006. https://doi.org/10.53388/2025825006

Advances in precision diagnosis and treatment, and translational medicine research for refractory relapsed multiple myeloma

Wei Fu[1#*], Jun-Li Wang[2#], Guo-Bin Cheng[1], Lin-Ya Lyu[1], Hu-Lin Wang[3*]

[1]Department of Gastroenterology, 925th Hospital of PLA Joint Logistics Support Force, Guiyang 550009, China. [2]Department of Ultrasound, The Air Force Hospital of Southern Theater Command, Guangzhou 510030, China. [3]Department of Gerontology, 925th Hospital of PLA Joint Logistics Support Force, Guiyang 550009, China.

[#]These authors contributed equally to this work and are co-first authors for this paper.

[*]**Correspondence to:** Wei Fu, Department of Gastroenterology, 925th Hospital of PLA Joint Logistics Support Force, No. 67, Huanghe Road, Guiyang 510009, China. E-mail: fmmufw@foxmail.com. Hu-Lin Wang, Department of Gerontology, 925th Hospital of PLA Joint Logistics Support Force, No. 67, Huanghe Road, Guiyang 510009, China. E-mail: wanghulin@netease.com.

Abstract

Multiple myeloma is a complex and challenging blood cancer, particularly in cases where the disease has relapsed or become resistant to treatment. These situations often have a significant impact on both patient survival and quality of life. Over recent years, advances in precision medicine and translational medicine have brought about a shift in treatment strategies, moving toward more personalized and targeted approaches. This review highlights the latest developments in the management of refractory and relapsed multiple myeloma, focusing on the current state of precision diagnosis and treatment, the role of translational medicine, and potential future directions in research. By reviewing key studies and clinical trial data, we aim to offer fresh perspectives and strategies that could improve clinical outcomes.

Keywords: multiple myeloma; refractory relapsed; precision medicine; translational medicine; treatment strategies

Author contributions

Fu W, Lyu LY, Wang JL contributed to literature retrieval. Fu W, Cheng GB wrote the manuscript. Fu W, Wang HL conceived the study. All authors read and approved the whole manuscript to submit the *Cancer Advances*.

Competing interests

The authors declare no conflicts of interest.

Acknowledgments

This work was partially supported by grants from the 925th Science Foundation (Grant Nos. 2023-3 and 2024-2/3).

Peer review information

Cancer Advances thanks all anonymous reviewers for their contribution to the peer review of this paper.

Abbreviations

MM, multiple myeloma; RRMM, relapsed and refractory multiple myeloma; BCMA, b-cell maturation antigen; ctDNA, circulating tumor DNA; CAR, chimeric antigen receptor; OS, overall survival; CRS, cytokine release syndrome; NK, natural killer; AI, artificial intelligence; ML, machine learning.

Citation

Fu W, Wang JL, Cheng GB, Lyu LY, Wang HL. Advances in precision diagnosis and treatment, and translational medicine research for refractory relapsed multiple myeloma. *Cancer Adv*. 2025;8:e25006. doi: 10.53388/2025825006.

Executive editor: Jian Jia.

Received: 30 December 2024; **Revised:** 24 February 2025; **Accepted:** 18 March 2025; **Available online:** 26 March 2025.

Background

Multiple myeloma (MM) is a complex and varied blood cancer caused by the abnormal growth of plasma cells in the bone marrow. Its global incidence has been steadily rising, especially among older adults. Research shows a significant increase in MM cases in people over 60, which can be attributed not only to an aging population but also to improved survival rates thanks to advances in treatment options [1]. MM presents a variety of clinical challenges, especially in cases where the disease has relapsed or become resistant to standard therapies. Managing MM is particularly difficult due to its diverse biological characteristics, which can lead to widely differing outcomes among patients. While some individuals achieve prolonged survival, others experience rapid disease progression despite aggressive treatment [2].

The underlying biology of MM is complex, driven by various genetic abnormalities like chromosomal translocations and mutations that contribute to both disease progression and resistance to treatment. For example, chromosomal translocations such as t(11;14) contribute to the pathogenesis of MM by driving the overexpression of anti-apoptotic proteins like BCL2 [3]. Epimutations, which refer to heritable changes in gene expression that do not involve alterations in the DNA sequence.

For instance, specific translocations such as t(11;14) have been linked to a dependency on the anti-apoptotic protein BCL2, which has opened the door for targeted therapies like venetoclax [4]. However, one of the biggest challenges lies in accurately identifying the genetic and molecular landscape of the disease, a critical step in tailoring effective treatments. This has sparked interest in precision medicine as a promising approach to improve treatment outcomes [5].

Closely connected to precision medicine is translational medicine, which aims to bring research findings directly into clinical practice. In the context of MM, translational research has emphasized the importance of biomarker-driven therapies and the value of less invasive monitoring techniques, such as liquid biopsies, to track disease progression [6]. These advancements highlight the potential for developing targeted treatments that address the complexities of MM. Moreover, the incorporation of novel therapeutic agents, including monoclonal antibodies and small molecule inhibitors, illustrates how treatment paradigms are evolving to improve patient outcomes [7]. By leveraging genetic insights and advancing treatment options, healthcare providers are better equipped to navigate the challenges of relapsed and refractory MM, ultimately improving outcomes for patients [8]. Additionally, novel antibody drugs such as elotuzumab and selinexor, as well as bispecific antibodies teclistamab and talquetamab, are currently undergoing clinical research with promising outcomes [9]. Especially in the field of immunotherapy, such as chimeric antigen receptor (CAR) T cells, bispecific T cell engager antibodies, antibody drug conjugates, newer generations of monoclonal antibodies, and small molecule inhibitors and modulators [10].

A comprehensive literature search was conducted in the PubMed database to identify publications related to 'relapsed and refractory multiple myeloma' (RRMM) from January 2021 to December 2024. The search criteria were restricted to articles and reviews in the English language, yielding a total of 781 relevant documents. Employing the R package *bibliometrix* (version 4.2.3), a bibliometric analysis was performed to quantify and visualize the scientific output. This analysis facilitated the selection of ten seminal clinical papers (Table 1), distinguished by their impact factors and citation frequencies, which are considered indicative of their scholarly influence and relevance in the field.

In the realm of MM research, key terminology has surfaced, reflecting the current focal points and trends within the field. The disease focus is evident with terms such as 'MM' and 'RRMM', highlighting a concentrated interest in both the condition and its treatment-resistant or recurrent forms. The therapeutic landscape is marked by an emphasis on pharmaceuticals, with names like daratumumab, carfilzomib, pomalidomide, lenalidomide, bortezomib, elotuzumab, isatuximab, selinexor, and melflufen indicating a significant research effort directed towards these agents.

The significance of clinical research is underscored by terms like 'clinical trial' and 'real-world', which denote the value placed on empirical studies and practical application. Additionally, the focus on 'efficacy' and 'safety' underscores the paramount importance of assessing both the therapeutic outcomes and the well-being of patients. Advances in immunotherapy are reflected through terms such as 'immunotherapy' and 'CAR-T', indicating a pivot towards harnessing the immune system in treatment strategies.

The pursuit of biomarkers is indicated by keywords 'b-cell maturation antigen' (BCMA), which may serve as targets for therapeutic intervention. The interest in treatment strategies is evident with terms like 'bispecific antibodies' and 'monoclonal antibodies,' indicating an ongoing exploration of novel approaches to combat the disease. Furthermore, the term 'cytokine release syndrome' (CRS) likely pertains to the investigation of immunotherapy-associated side effects.

Collectively, these keywords encapsulate the principal avenues of MM research, encompassing disease characteristics, therapeutic pharmaceuticals, clinical trial design, efficacy assessment, immunotherapeutic advancements, biomarker identification, and strategic treatment approaches (Figure 1).

Advances in precision diagnosis and treatment of refractory relapsed multiple myeloma

Biomarkers of refractory relapsed MM

Advances in genomics and epigenomics research. Recent breakthroughs in genomics and epigenomics have greatly advanced our understanding of RRMM. Genomic research has uncovered a range of genetic mutations and chromosomal abnormalities that play key roles in the development and progression of myeloma. Mutations in genes like TP53, KRAS, and NRAS have been linked to poor prognosis and resistance to treatment [11]. The introduction of next-generation sequencing has further deepened our knowledge of the myeloma genome, uncovering intricate mutational patterns and clonal heterogeneity – factors that can complicate how patients respond to therapy [12].

On the epigenetic side, changes in DNA methylation and histone modifications have been found to influence myeloma progression by altering gene expression without changing the underlying DNA sequence. These epigenetic alterations can silence tumor suppressor genes or activate oncogenes, effectively driving tumor growth and progression [13]. The interaction between genetic mutations and epigenetic changes plays a critical role in understanding why drug resistance and disease relapse occur in myeloma patients.

Impact of the immune microenvironment. The immune microenvironment plays a crucial role in the progression and treatment response of RRMM. Myeloma tumor cells have the ability to create an immunosuppressive environment that hampers effective immune responses. Within this environment, certain immune cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells, infiltrate the tumor and contribute to immune evasion. They do so by suppressing T cell activation, which ultimately promotes tumor growth [14]. The interaction between myeloma cells and the bone marrow microenvironment is equally significant, as it provides essential survival signals that support the tumor cells and promote drug resistance [15]. Specific cytokines and growth factors present in this microenvironment can strengthen the survival and proliferation of myeloma cells. Furthermore, recent research has shed light on the role of immune checkpoint molecules, like PD-1 and CTLA-4, which are upregulated in the myeloma microenvironment. These molecules add another layer of immune suppression, allowing tumor cells to evade immune attack [16].

A deeper understanding of the immune microenvironment in RRMM is key to advancing treatment strategies. Novel immunotherapeutic approaches, such as immune checkpoint inhibitors and CAR T-cell therapies, aim to restore and enhance the immune system's ability to

fight myeloma. These therapies hold great promise in overcoming the immune suppression seen in RRMM and improving patient outcomes (Figure 2).

Discovery and application of novel biomarkers. The discovery of new biomarkers for RRMM is a highly active area of research, with the potential to significantly improve diagnosis, prognosis, and treatment monitoring. Recent advancements in fields like proteomics and metabolomics have allowed researchers to identify specific protein and metabolite profiles linked to RRMM. These profiles could serve as biomarkers to track disease progression and predict treatment responses [17]. For instance, elevated levels of cytokines like IL-6 and IL-10 have been associated with a poorer prognosis in patients with MM [18].

Table 1 Highly cited publications on RRMM

Acronym	Study title	Class/mechanism of action	Study design	Study start date	Journal	Impact factor	Citations
CARTITUDE-1	Ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: cartitude-1 2-year follow-up	CAR T-cell therapy	Single-arm	06/06/2022	JOURNAL OF CLINICAL ONCOLOGY	42.1	91
Myeloma CAR T	Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium	CAR T-cell therapy	Real-world	09/01/2023	JOURNAL OF CLINICAL ONCOLOGY	42.1	39
ABBV-383	A phase I first-in-human study of ABBV-383 in patients with relapsed/refractory multiple myeloma	Bispecific T-cell Redirecting Antibody	Single-arm	27/08/2022	JOURNAL OF CLINICAL ONCOLOGY	42.1	33
UNIVERSAL	Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results	Allogeneic CAR T-cell therapy	Single-arm	23/01/2023	NATURE MEDICINE	58.7	32
LEGEND-2	Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)	CAR T-cell therapy	Single-arm	06/07/2022	JOURNAL OF HEMATOLOGY & ONCOLOGY	29.5	32
CRS	CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies	CAR T-cell therapy	–	09/09/2022	NATURE COMMUNICATIONS	14.7	24
ICARIA-MM	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics	CAR T-cell therapy	–	26/05/2021	BRITISH JOURNAL OF HAEMATOLOGY	5.1	19
Bispecific Abs	Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis	Bispecific Antibody	Pooled analysis	01/03/2023	BLOOD ADVANCES	7.4	18
Ide-cel	Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma	CAR T-cell therapy	–	08/08/2022	BLOOD ADVANCES	7.4	17
CT103A	A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma	Fully human BCMA-targeting CAR	Single-arm	29/01/2021	BLOOD	21	16

Cancer Advances 2025;8:e25006. https://doi.org/10.53388/2025825006



Figure 1 Illustrates a word cloud representing the prevalence of keywords in the research pertaining to RRMM



Figure 2 Synthetic CARs recognize tumor-associated antigens on the surface of cancer cells through the single-chain variable fragment (scFv) domain

Another exciting development is the use of circulating tumor DNA (ctDNA) analysis, which is emerging as a promising tool for monitoring disease burden and detecting minimal residual disease in RRMM [19]. By applying these novel biomarkers in clinical practice, clinicians could adopt more personalized treatment approaches, enabling timely therapy adjustments based on an individual patient's response.

Moreover, integrating biomarker data with genomic and clinical information could enhance risk stratification and support more informed therapeutic decisions. This combination of data could ultimately lead to better outcomes for patients. The current sequencing methodologies exhibit limitations in delineating spatial heterogeneity and demonstrate insufficient sensitivity for reliable minimal residual disease detection through liquid biopsy platforms. Achieving precise molecular characterization necessitates the adoption of advanced analytical approaches, such as phased variant sequencing, to overcome these technical constraints. Furthermore, substantial inter-laboratory variability in critical workflow components – including pre-analytical sample processing, detection methodologies, and bioinformatic pipelines – compromises result comparability and reproducibility. This standardization deficit undermines the clinical utility and diagnostic accuracy of ctDNA assessments. Notably, the substantial costs associated with high-resolution ctDNA profiling present a formidable barrier to its widespread implementation in mm management, particularly for longitudinal disease surveillance and molecular risk stratification [20].

Current status of precision therapeutic strategies

Development and application of targeted therapeutic agents. The development of targeted therapies has revolutionized cancer treatment, offering more personalized and effective options for patients. For instance, the CARTITUDE-1 trial reported a 97% overall response rate and 27-month PFS and overall survival (OS) rates were 54.9% and 70.4% [21]. Additionally, the Myeloma CAR T Consortium reported a 84% overall response rate and a median OS of 12.5 months in a real-world setting [22].

To overcome the challenges in precise treatment, combination therapies and the use of novel agents such as bispecific antibodies are being explored to address resistance to current treatments [23].

These therapies are specifically designed to block molecular pathways that are essential for tumor growth and survival, reducing harm to normal cells in the process. Advances in molecular biology and genomics have made it possible to identify precise molecular targets, leading to the creation of a variety of targeted therapeutic agents. Treatments targeting the BCMA have shown remarkable success in MM, producing significant clinical responses in patients with relapsed and refractory disease [24].

Despite these advancements, drug resistance – both intrinsic and acquired – continues to pose a major challenge to the effectiveness of targeted therapies. Resistance mechanisms may involve changes to the target itself or the activation of alternative pathways that allow the tumor to bypass the treatment. To address these issues, researchers are exploring combination therapies that target multiple pathways simultaneously, with the aim of improving treatment outcomes. In addition, dual-targeted therapies are being studied as a way to disrupt multiple signaling pathways that cancer cells rely on for survival, further increasing the potential for overcoming resistance [25].

Another key area of ongoing research is the discovery of biomarkers that can predict how patients will respond to targeted therapies. These

biomarkers are critical for advancing precision medicine, as they allow clinicians to tailor treatments based on a patient's individual profile, ultimately improving effectiveness while minimizing unnecessary side effects [26].

Application of immunotherapy in RRMM. Innovations like immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies have transformed the treatment landscape, offering new hope to patients with few remaining options. CAR T-cell therapy, which targets specific antigens on myeloma cells such as BCMA, has shown exceptional effectiveness in clinical trials, delivering rapid and long-lasting responses in patients who have undergone extensive prior treatments [27].

However, significant challenges remain. The complexity of the tumor microenvironment and the possibility of antigen escape – where myeloma cells change to evade immune targeting – can lead to treatment failure [28]. To address these challenges, the integration of bispecific T-cell engagers into treatment strategies has emerged as a promising solution. Bispecific T-cell engagers work by redirecting T cells to target myeloma cells more efficiently, further strengthening the immunotherapy toolkit for this disease [29]. By combining immunotherapies with other treatments, such as targeted therapies and traditional chemotherapy, clinicians hope to improve outcomes and extend survival for patients with this challenging condition [30].

CAR T-cell therapy has demonstrated remarkable progress in MM management, achieving significantly improved response rates and survival benefits. However, longitudinal analyses reveal persistent relapse patterns in subsets of patients, with OS influenced by patient-specific variables (e.g., genetic predisposition, immune microenvironment) and tumor cell-intrinsic factors (e.g., antigen escape, clonal evolution), necessitating continued longitudinal investigation. Regarding safety profiles, the therapy remains challenged by CRS and immune effector cell-associated neurotoxicity syndrome, though these adverse events are effectively managed through standardized protocols incorporating tocilizumab, corticosteroids, and best supportive care. Current strategies to enhance therapeutic durability focus on three pillars: (1) refining cellular products through next-generation CAR-T constructs with bispecific or multi-targeted CAR architectures; (2) development of combination regimens integrating CAR-T therapy with immunomodulatory agents or checkpoint inhibitors; (3) optimizing treatment protocols through enhanced patient management and real-time biomarker-guided intervention. These multidimensional advancements collectively address current limitations while expanding the therapeutic window in relapsed/refractory MM [31].

Cutting-edge research in cellular therapies. Cellular therapies represent an exciting and rapidly advancing area in the treatment of cancers, including MM. These approaches leverage immune cells, such as T cells and natural killer (NK) cells, that are either engineered or activated to enhance their ability to identify and destroy cancer cells. Among these, the development of CAR T-cell therapies has been especially groundbreaking. These engineered T cells are designed to specifically recognize and attack tumor antigens, achieving remarkable clinical responses in patients with relapsed or refractory disease [32].

NK cell therapies are also gaining attention for their unique ability to naturally detect and kill tumor cells without prior sensitization. This characteristic makes them a promising 'off-the-shelf' treatment option that can be quickly deployed [32]. Researchers are actively working to improve the effectiveness and safety of both CAR T-cell and NK cell therapies by addressing challenges such as the longevity of infused cells and the management of potential side effects [29].

Another promising avenue involves combining cellular therapies with other treatments, such as immunotherapies and targeted therapies. These combination approaches aim to enhance therapeutic outcomes and achieve more durable responses in patients with advanced malignancies [30].

The application of translational medicine in MM

The integration of clinical trials and basic research. In the case of MM, this approach has led to the discovery of specific genetic mutations and molecular pathways that drive the disease. These breakthroughs have directly influenced the creation of targeted therapies, such as proteasome inhibitors and immunomodulatory drugs, which have significantly improved outcomes for patients.

The success of clinical trials involving these targeted treatments can be traced back to foundational research that uncovered the mechanisms behind MM's progression. Additionally, clinical trials act as a feedback loop for basic research, offering valuable insights from patient responses that help scientists refine their hypotheses and strategies. This dynamic interaction accelerates the pace of discovery while ensuring that research remains closely aligned with the needs of patients. Ultimately, this synergy enhances the development of new and more effective therapies for treating MM [33, 34].

The translational pathway from laboratory to clinic. The process of translating laboratory discoveries into clinical practice for MM involves several essential steps, including preclinical validation, clinical trial design, and regulatory approval. It begins with basic research that identifies potential therapeutic targets, which are then rigorously tested in preclinical studies using cell lines and animal models. These studies are critical for demonstrating both the safety and effectiveness of a treatment before it can move on to human trials.

Successfully overcoming these hurdles is vital for ensuring that innovative treatments reach patients in a timely manner. The ever-evolving field of translational medicine highlights the importance of collaboration among researchers, clinicians, and regulatory bodies to streamline this process. By working together, these stakeholders can accelerate the development and delivery of effective new therapies to improve outcomes for MM patients [35, 36].

Patient-centered research models. Incorporating patient perspectives into translational research is crucial to ensure that the therapies developed truly address the needs of individuals living with MM. By engaging patients, researchers can gain valuable insights into the lived experiences, challenges, and preferences of those affected by MM. This, in turn, helps shape interventions that are both more relevant and effective.

Patient-reported outcomes are increasingly being used in clinical trials to evaluate how treatments impact quality of life, symptom management, and overall satisfaction with care. This approach not only makes research findings more meaningful but also encourages a sense of ownership and involvement among patients, which can lead to better recruitment and retention in clinical studies. In real-world clinical practice, the optimization of personalized therapeutic strategies can be achieved through systematic integration of patient feedback and engagement. Key approaches include: (1) enhancing physician-patient communication to align treatment goals with patient preferences; (2) precise utilization of patient-reported outcome instruments for real-time symptom monitoring; (3) implementation of shared decision-making models to reconcile clinical evidence with individual values; (4) establishment of multidisciplinary collaborative frameworks incorporating hematology, nursing, and psychosocial expertise; (5) adoption of iterative assessment protocols for dynamic treatment modification. This comprehensive paradigm synergistically enhances patient adherence, improves therapeutic outcomes, and reduces treatment-related morbidity in MM management [37].

Ultimately, a patient-centered approach in translational medicine fosters a more holistic understanding of MM. It ensures that the therapies being developed align closely with patient priorities and values, leading to improved care and outcomes for those living with this challenging disease [38, 39].

The impact of emerging technologies on precision diagnosis and treatment

Application of single-cell sequencing technology. Future research endeavors and clinical interventions in the realm of MM have been illuminated by fresh perspectives. The identified gene expression patterns and molecular pathways hold substantial promise as therapeutic targets for the treatment of MM. The employment of single-cell RNA sequencing (scRNA-seq) technology has significantly

advanced our precise understanding of the intricate cellular processes and interactions within MM [40]. The application of single-cell technology holds the potential to address prominent issues in myeloma biology and has revolutionized our understanding of intra-tumoral and inter-tumoral heterogeneity, the tumor microenvironment, and mechanisms of treatment resistance in MM [41].

Single-cell sequencing technology has significantly advanced our precise understanding of the intricate cellular processes and interactions within MM. However, it is important to note that single-cell sequencing technologies can be prohibitively expensive and require sophisticated bioinformatics tools for data analysis, which may limit their widespread adoption in clinical settings [42]. Similarly, while artificial intelligence (AI) holds great promise, challenges such as algorithm bias and the need for large, high-quality datasets remain significant hurdles [43].

This advanced technology allows researchers to analyze individual cells in extraordinary detail, providing critical insights into cellular heterogeneity – an essential factor in understanding tumor biology. Unlike traditional bulk sequencing methods, which often obscure the unique traits of rare cell populations within tumors, single-cell sequencing uncovers the genetic, transcriptomic, and epigenetic profiles of individual cells. This helps reveal the complexities of the tumor microenvironment and the clonal evolution of cancer cells [44].

One of the most valuable applications of single-cell sequencing is its ability to identify specific subclonal populations that may play key roles in driving tumor progression or contributing to resistance to therapies. By linking single-cell data with clinical outcomes, researchers can create more precise and effective treatment strategies tailored to the unique profiles of individual patients [45].

Furthermore, recent advancements in single-cell sequencing technologies, such as long-read sequencing and spatial transcriptomics, are pushing the boundaries of what these tools can achieve. These innovations enhance the resolution and clinical relevance of single-cell analyses, making them even more applicable in real-world healthcare settings [46].

The role of AI and machine learning (ML) in data analysis. MM ranks among the most prevalent hematological malignancies globally, and due to its high recurrence rate and robust resistance to chemotherapy, it is one of the most challenging tumors to cure. Research leveraging ML and deep learning is poised to become a strategic approach in the future for tackling this poorly prognostic tumor by detecting new biomarkers for its rapid identification and treatment selection, as well as for better assessing its recurrence and survival outcomes [47].

AI and ML are transforming the way medical data is analyzed, particularly in the field of precision medicine. These advanced technologies can process and interpret vast amounts of data from various sources, such as genomic sequencing, electronic health records, and imaging studies. By using sophisticated algorithms, AI and ML can uncover patterns and correlations that may not be immediately obvious to human analysts, enhancing both diagnostic accuracy and treatment effectiveness [48].

In medical imaging, AI-powered tools are being used to automate the interpretation of radiological scans, making diagnoses faster and more reliable while minimizing the risk of human error [49]. Additionally, ML models have been developed to predict patient outcomes by analyzing historical data. These models enable clinicians to create more personalized treatment plans that take into account an individual's unique characteristics and disease progression [50].

Despite their potential, challenges remain. AI models need robust validation in diverse clinical settings to ensure their reliability, and ethical concerns related to data privacy and algorithmic bias must be addressed [51]. Even so, the integration of AI and ML holds great promise for revolutionizing healthcare, driving innovation in various industries, and ultimately improving the quality of life for people around the world, provided that the aforementioned challenges are properly tackled.

The implementation of advanced imaging analysis techniques, including AI and radiomics, brings great promise for deepening our understanding of MM. The integration of advanced image analysis techniques that extract features from magnetic resonance imaging, computed tomography, or positron emission tomography (PET) images has the potential to enhance the diagnostic accuracy of MM [52].

Recent advancements in imaging technologies have greatly expanded the possibilities for precision diagnosis and treatment across various medical fields. Cutting-edge modalities such as photoacoustic imaging (PAI), terahertz imaging, and high-resolution peripheral quantitative computed tomography are driving this progress [53]. These innovative tools offer unique advantages, including the ability to provide both functional and structural information, which is essential for early cancer detection and monitoring treatment responses.

For instance, PAI combines the high spatial resolution of optical imaging with the deep tissue penetration of ultrasound, making it particularly effective for visualizing tumor blood vessels and evaluating the success of therapies [54]. Similarly, terahertz imaging has emerged as a promising non-invasive technique for identifying cancerous tissues by leveraging their distinct optical properties, offering new potential for early cancer diagnosis [55].

The integration of these advanced imaging technologies with AI and ML further enhances their capabilities. This combination enables real-time analysis and interpretation of complex imaging data, improving diagnostic accuracy and speed [56].

Future research directions and challenges

The necessity of multidisciplinary collaboration. Multidisciplinary collaboration is increasingly recognized as a key factor in tackling complex health challenges that require input from a variety of expertise. For example, in the context of relapsed and refractory MM, molecular biologists can identify novel biomarkers, while data scientists can develop predictive models to guide treatment decisions, and clinicians can implement these findings in patient care [57, 58].

In healthcare, particularly in areas like oncology, cardiology, and chronic disease management, integrating knowledge from multiple disciplines has been shown to improve patient outcomes. Managing conditions like bronchiectasis highlights the need for a collaborative approach due to the high variability among patient groups, which makes identifying effective biomarkers and treatments more challenging [59].

Similarly, diseases such as cancer, with their complex biological and psychosocial dimensions, benefit greatly from a team-based approach. Collaboration among oncologists, radiologists, pathologists, and palliative care specialists ensures a more comprehensive understanding of each patient's needs, leading to the development of personalized treatment plans.

The integration of AI into clinical practice is another area where multidisciplinary teamwork is essential. While AI has the potential to revolutionize data analysis and predictive modeling, its effective implementation requires the combined efforts of clinicians, data scientists, and ethicists. This ensures that AI-driven solutions are not only clinically relevant but also ethically sound [60].

Ethical and policy considerations in clinical practice. The intersection of ethics and policy in clinical practice poses numerous challenges that demand thoughtful consideration. For example, ensuring patient data privacy in the context of large-scale genomic studies is a significant concern, and robust informed consent processes are essential to maintain patient trust [61].

As healthcare systems continue to evolve, particularly with the adoption of new technologies and treatments, ethical dilemmas often emerge around issues such as patient consent, confidentiality, and the fair allocation of resources. For example, the growing use of continuous glucose monitoring in diabetes management raises concerns about equitable access and the potential for disparities in care [62].

Similarly, the integration of AI into healthcare brings its own ethical complexities. Ensuring patient privacy, addressing potential biases in

algorithms, and maintaining trust in AI-driven decisions require ongoing collaboration among healthcare providers, policymakers, and ethicists [60]. In addition, clinicians often face ethical responsibilities in managing complex cases, such as those involving pediatric patients or individuals with chronic illnesses. These situations require a nuanced understanding of both clinical guidelines and the unique needs of individual patients.

The complexity of these issues underscores the importance of developing robust ethical frameworks and policies to guide clinical decision-making. Such frameworks should help practitioners prioritize patient welfare and autonomy while navigating the challenges posed by technological advancements and resource constraints. Moving forward, research must focus on creating comprehensive ethical guidelines that address these emerging challenges and promote best practices in patient care.

The realization of continuous monitoring and personalized treatment. Continuous monitoring and personalized treatment have emerged as transformative advancements in modern healthcare, particularly for managing chronic diseases like diabetes, cardiovascular conditions, and respiratory illnesses. Technologies such as wearable devices and mobile health applications now enable real-time data collection and analysis, allowing for timely interventions and tailored treatment plans. For instance, continuous glucose monitoring systems have revolutionized diabetes management by giving patients real-time insights into their blood glucose levels. This has led to better glycemic control and a reduced risk of complications [60].

Despite their potential, implementing these technologies presents challenges. Ensuring data accuracy, addressing privacy concerns, and effectively integrating these tools into clinical practice are all critical issues that need to be addressed. Personalizing treatment based on continuous monitoring data also requires a shift in healthcare delivery models. Greater emphasis must be placed on patient engagement and shared decision-making, where patients and clinicians work together to develop individualized care plans. Clinicians must also be trained to interpret the data accurately and communicate findings to patients in a way that is meaningful and actionable.

As healthcare systems adapt to these innovations, ongoing research is essential to assess the effectiveness of continuous monitoring in improving health outcomes. Additionally, identifying best practices for incorporating personalized treatment strategies into routine care will be key. Ultimately, the goal is to foster a healthcare environment that not only embraces these technological advancements but also prioritizes patient-centered care and individualized treatment approaches.

Conclusion

The diagnosis and treatment landscape for RRMM is undergoing rapid transformation, driven by advancements in precision medicine and translational research. Biomarker discovery has become a focal point, offering promising opportunities for targeted therapies that have the potential to significantly improve patient outcomes. With the help of cutting-edge technologies like next-generation sequencing and advanced imaging techniques, clinicians are increasingly able to adopt personalized treatment strategies tailored to the unique genetic and phenotypic profile of each patient's disease.

However, integrating these innovations into clinical practice presents significant challenges. Multidisciplinary collaboration among researchers, clinicians, and other healthcare professionals is essential to bridge the gap between foundational research and real-world application. These collaborations can accelerate the translation of laboratory breakthroughs into effective therapies, particularly for a disease as complex and heterogeneous as MM, which is often resistant to conventional treatments.

An ongoing dialogue between different research perspectives is also critical. While the promise of targeted therapies is substantial, it is important to balance these advances with a broader understanding of the disease's biological complexity. This includes recognizing the limitations of current therapies and the need for continuous exploration of new treatment modalities and combination strategies.

Ultimately, incorporating precision medicine into the management of RRMM holds the potential to transform patient outcomes. Equally important is fostering an adaptive research framework capable of addressing the disease's ever-evolving nature. By advancing our collective knowledge and encouraging collaboration within the medical community, we can better confront the challenges posed by this challenging malignancy. Moving forward, innovative diagnostics and therapeutics, strengthened by interdisciplinary partnerships, will play a pivotal role in reshaping the treatment landscape for MM. This will not only improve survival rates but also enhance the quality of life for patients living with this complex disease.

References

1. Vinogradova OY, Ptushkin VV, Chernikov MV, Kochkareva YB, Zherebtsova VA. Epidemiology of multiple myeloma in city Moscow. *Ter Arkh.* 2019;91(7):83–92. Available at: http://doi.org/10.26442/00403660.2019.07.000305
2. Waszczuk-Gajda A, Szafraniec-Buryło S, Kraj L, et al. Epidemiology of multiple myeloma in Poland in the years 2008–2017. *Arch Med Sci.* 2020;19(3):645–650. Available at: http://doi.org/10.5114/aoms.2020.92908
3. Portuguese AJ, Banerjee R, Chen G, et al. Novel Treatment Options for Multiple Myeloma. *JCO Oncol Pract.* 2025:OP2400752. Available at: http://doi.org/10.1200/OP-24-00752
4. Diamantidis MD, Papadaki S, Hatjiharissi E. Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. *Front Oncol.* 2022;12:934008. Available at: http://doi.org/10.3389/fonc.2022.934008
5. Pan D, Richter J. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. *Front Oncol.* 2022;11:819127. Available at: http://doi.org/10.3389/fonc.2021.819127
6. Ferreira B, Caetano J, Barahona F, et al. Liquid biopsies for multiple myeloma in a time of precision medicine. *J Mol Med (Berl).* 2020;98(4):513–525. Available at: http://doi.org/10.1007/s00109-020-01897-9
7. Jeryczynski G, Bolomsky A, Agis H, Krauth MT. Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. *Cancers.* 2021;13(23):5886. Available at: http://doi.org/10.3390/cancers13235886
8. Morè S, Corvatta L, Manieri VM, Olivieri A, Offidani M. Current Main Topics in Multiple Myeloma. *Cancers.* 2023;15(8):2203. Available at: http://doi.org/10.3390/cancers15082203
9. Chen Q, Zhang M, Zheng S, et al. Therapeutic progress in relapsed/refractory multiple myeloma. *Ann Hematol.* 2024;103(6):1833–1841. Available at: http://doi.org/10.1007/s00277-024-05730-y
10. Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR - T and beyond. *J Hematol Oncol.* 2021;14(1):115. Available at: http://doi.org/10.1186/s13045-021-01109-y
11. Lee JS, Kim NS. Genomic perspectives on epigenetics. Genes Genomics. *Genes Genomics.* 2022;44(3):247–249. Available at: http://doi.org/10.1007/s13258-022-01225-0
12. Mohammad A, Jha S. Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment. *Cancers.* 2022;15(1):215. Available at: http://doi.org/10.3390/cancers15010215
13. Yi SV, Goodisman MAD. The impact of epigenetic information on genome evolution. *Philos Trans R Soc Lond B Biol Sci.* 2021;376(1826):20200114. Available at: http://doi.org/10.1098/rstb.2020.0114
14. Lamplugh Z, Fan Y. Vascular Microenvironment, Tumor

Immunity and Immunotherapy. *Front Immunol.* 2021;12:811485. Available at: http://doi.org/10.3389/fimmu.2021.811485
15. Liang XH, Chen XY, Yan Y, et al. Targeting metabolism to enhance immunotherapy within tumor microenvironment. *Acta Pharmacol Sin.* 2024;45(10):2011–2022. Available at: http://doi.org/10.1038/s41401-024-01304-w
16. Kim A, Lim SM, Kim JH, Seo JS. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma. *Front Immunol.* 2021;12:598671. Available at: http://doi.org/10.3389/fimmu.2021.598671
17. Kasuga K. To move from CSF biomarkers to blood biomarkers. *Nippon Ronen Igakkai Zasshi.* 2024;61(1):28–33. Available at: http://doi.org/10.3143/geriatrics.61.28
18. Kurtin SE, Henglefelt A, Price A, et al. Biomarker Jeopardy. *J Adv Pract Oncol.* 2021;12(3):285–288. Available at: http://doi.org/10.6004/jadpro.2021.12.3.13
19. Ponzini E. Tear biomarkers. *Adv Clin Chem.* 2024:69–115. Available at: http://doi.org/10.1016/bs.acc.2024.03.002
20. Hosoya H, Carleton M, Tanaka K, et al. Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma. *Nat Commun.* 2025;16(1):1824. Available at: http://doi.org/10.1038/s41467-025-56486-6
21. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. *J Clin Oncol.* 2023;41(6):1265–1274. Available at: http://doi.org/10.1200/JCO.22.00842
22. Hansen DK, Sidana S, Peres LC, et al. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. *J Clin Oncol.* 2023;41(11):2087–2097. Available at: http://doi.org/10.1200/JCO.22.01365
23. Zhou X, Einsele H, Danhof S. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. *J Clin Med.* 2020;9(7):2166. Available at: http://doi.org/10.3390/jcm9072166
24. Yu B, Jiang T, Liu D. BCMA - targeted immunotherapy for multiple myeloma. *J Hematol Oncol.* 2020;13(1):125. Available at: http://doi.org/10.1186/s13045-020-00962-7
25. Wang W, Sun Y, Liu X, Kumar SK, Jin F, Dai Y. Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. *Front Oncol.* 2022;12:859455. Available at: http://doi.org/10.3389/fonc.2022.859455
26. Middleton G, Robbins H, Andre F, Swanton C. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer. *Ann Oncol.* 2022;33(2):143–157. Available at: http://doi.org/10.1016/j.annonc.2021.11.004
27. Ding H, Wu Y. CAR-T Therapy in Relapsed Refractory Multiple Myeloma. *Curr Med Chem.* 2024;31(27):4362–4382. Available at: http://doi.org/10.2174/0109298673268932230920063933
28. Shi X, Wu Y, Yao X, Du B, Du X. Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma. *Front Immunol.* 2024;15:1422478. Available at: http://doi.org/10.3389/fimmu.2024.1422478
29. Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J. Inmunoterapia en el mieloma múltiple. *Med Clin (Barc).* 2024;162(10):485–493. Available at: http://doi.org/10.1016/j.medcli.2023.11.019
30. Boussi LS, Avigan ZM, Rosenblatt J. Immunotherapy for the treatment of multiple myeloma. *Front Immunol.* 2022;13:1027385. Available at: http://doi.org/10.3389/fimmu.2022.1027385
31. Besliu C, Tanase AD, Rotaru I, et al. The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies. *Cancers.* 2025;17(3):525. Available at: http://doi.org/10.3390/cancers17030525
32. Roshandel E, Ghaffari-Nazari H, Mohammadian M, et al. NK cell therapy in relapsed refractory multiple myeloma. *Clin Immunol.* 2023;246:109168. Available at: http://doi.org/10.1016/j.clim.2022.109168
33. Mittelman M. TRANSLATIONAL MEDICINE IN MALIGNANT HEMATOLOGY. *Harefuah.* 2024;163(2):125–132. Available at: https://pubmed.ncbi.nlm.nih.gov/38431863/
34. Ioachimescu OC, Shaker R. Translational science and related disciplines. *J Investig Med.* 2024;73(1):3–26. Available at: http://doi.org/10.1177/10815589241283515
35. Cota-Romero CF, Aquino-Jarquin G. Significant challenges to translating breakthrough science in Mexico. *Trends Mol Med.* 2024::S1471-4914(24)00278-8. Available at: http://doi.org/10.1016/j.molmed.2024.10.011
36. Blum A. TRANSLATIONAL MEDICINE - THE FRONTLINE OF MEDICAL RESEARCH. *Harefuah.* 2024;163(2):85–87. Available at: http://pubmed.ncbi.nlm.nih.gov/38431855/
37. Laane E, Salek S, Oliva EN, et al. Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials. *Cancers.* 2023;15(24):5764. Available at: http://doi.org/10.3390/cancers15245764
38. Nakao K. Translational science: Newly emerging science in biology and medicine – Lessons from translational research on the natriuretic peptide family and leptin. *Proc Jpn Acad Ser B Phys Biol Sci.* 2019;95(9):538–567. Available at: http://doi.org/10.2183/pjab.95.037
39. Abrams ED, Basu A, Zavorka Thomas ME, Henrickson SE, Abraham RS. Expanding the diagnostic toolbox for complex genetic immune disorders. *J Allergy Clin Immunol.* 2025;155(2):255–274. Available at: http://doi.org/10.1016/j.jaci.2024.11.022
40. Li X, Lin Z, Zhao F, et al. Unveiling the cellular landscape: insights from single-cell RNA sequencing in multiple myeloma. *Front Immunol.* 2024;15:1458638. Available at: http://doi.org/10.3389/fimmu.2024.1458638
41. Chen M, Jiang J, Hou J. Single - cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications. *Biomark Res.* 2023;11(1):55. Available at: http://doi.org/10.1186/s40364-023-00502-8
42. Ruta A, Krishnan K, Elisseeff JH. Single - cell transcriptomics in tissue engineering and regenerative medicine. *Nat Rev Bioeng.* 2024;2:101–119. Available at: http://doi.org/10.1038/s44222-023-00132-7
43. Ricci Lara MA, Echeveste R, Ferrante E. Addressing fairness in artificial intelligence for medical imaging. *Nat Commun.* 2022;13:4581. Available at: http://doi.org/10.1038/s41467-022-32186-3
44. Melnekoff DT, Laganà A. Single - Cell Sequencing Technologies in Precision Oncology. *Adv Exp Med Biol.* 2022;1361:269–282. Available at: http://doi.org/10.1007/978-3-030-91836-1_15
45. Bai X, Li Y, Zeng X, Zhao Q, Zhang Z. Single-cell sequencing technology in tumor research. *Clin Chim Acta.* 2021;518:101–109. Available at: http://doi.org/10.1016/j.cca.2021.03.013
46. Gupta P, O'Neill H, Wolvetang EJ, Chatterjee A, Gupta I. Advances in single-cell long-read sequencing technologies. *NAR Genom Bioinform.* 2024;6(2):lqae047. Available at: http://doi.org/10.1093/nargab/lqae047
47. Allegra A, Tonacci A, Sciaccotta R, et al. Machine Learning and

Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection. *Cancers.* 2022;14(3):606. Available at: http://doi.org/10.3390/cancers14030606

48. Allen B. Discovering Themes in Deep Brain Stimulation Research Using Explainable Artificial Intelligence. *Biomedicines.* 2023;11(3):771. Available at: http://doi.org/10.3390/biomedicines11030771
49. Nabi W, Bansal A, Xu B. Applications of artificial intelligence and machine learning approaches in echocardiography. *Echocardiography.* 2021;38(6):982–992. Available at: http://doi.org/10.1111/echo.15048
50. Rattan P, Penrice DD, Simonetto DA. Artificial Intelligence and Machine Learning: What You Always Wanted to Know but Were Afraid to Ask. *Gastro Hep Adv.* 2022;1(1):70–78. Available at: http://doi.org/10.1016/j.gastha.2021.11.001
51. Anderson D. Artificial Intelligence and Applications in PM&R. *Am J Phys Med Rehabil.* 2019;98(11):e128–e129. Available at: http://doi.org/10.1097/PHM.0000000000001171
52. Michalska - Foryszewska A, Rogowska A, Kwiatkowska - Miernik A, et al. Role of Imaging in Multiple Myeloma: A Potential Opportunity for Quantitative Imaging and Radiomics. *Cancers (Basel).* 2024;16(23):4099. Available at: http://doi.org/10.3390/cancers16234099
53. Jiang D, Zhu L, Tong S, Shen Y, Gao F, Gao F. Photoacoustic imaging plus X: a review. *J Biomed Opt.* 2023;29(S1):S11513. Available at: http://doi.org/10.1117/1.JBO.29.S1.S11513
54. Tadros SS, Epsley S, Mehta S, et al. The Application of Advanced Bone Imaging Technologies in Sports Medicine. *Radiol Res Pract.* 2023:7412540. Available at: http://doi.org/10.1155/2023/7412540
55. Gezimati M, Singh G. Advances in terahertz technology for cancer detection applications. *Opt Quantum Electron.* 2023;55(2):151. Available at: http://doi.org/10.1007/s11082-022-04340-0
56. Krajcer Z. Artificial Intelligence in Cardiovascular Medicine: Historical Overview, Current Status, and Future Directions. *Tex Heart Inst J.* 2022;49(2):e207527. Available at: http://doi.org/10.14503/THIJ-20-7527
57. Myrhøj CB, Viftrup DT, Jarden M, et al. Interdisciplinary collaboration in serious illness conversations in patients with multiple myeloma and caregivers - a qualitative study. *BMC Palliat Care.* 2023;22(1):93. Available at: http://doi.org/10.1186/s12904-023-01221-5
58. Karathanasis N, Spyrou GM. Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data. *Cancers.* 2025;17(2):332. Available at: http://doi.org/10.3390/cancers17020332
59. Amaro R, Perea L, Sibila O. Future Directions in Bronchiectasis Research. *Clin Chest Med.* 2022;43(1):179–187. Available at: http://doi.org/10.1016/j.ccm.2021.12.005
60. Sebastian AM, Peter D. Artificial Intelligence in Cancer Research: Trends, Challenges and Future Directions. *Life.* 2022;12(12):1991. Available at: http://doi.org/10.3390/life12121991
61. Sisodiya SM. Precision medicine and therapies of the future. *Epilepsia.* 2020;62(S2):S90-S105. Available at: http://doi.org/10.1111/epi.16539
62. Miller E. Continuous Glucose Monitoring in Practice. *J Fam Pract.* 2023;72(6Suppl):S13-S18. Available at: http://doi.org/10.12788/jfp.0568